KW-2449 is a potent inhibitor of Aurora kinases, a family of enzymes involved in cell division and mitosis. Due to its ability to selectively target Aurora A and B kinases, it has been investigated primarily for its anticancer properties. It disrupts proper chromosome alignment and cytokinesis, leading to apoptosis in rapidly dividing tumor cells. This makes it a candidate for use in hematological malignancies and solid tumors, particularly where dysregulated cell division plays a key role. Research has focused on its efficacy in leukemia and lymphoma models, showing promise in inducing cell cycle arrest and reducing tumor growth. Its application remains within experimental and preclinical therapeutic development, often in combination with other chemotherapeutic agents to enhance antitumor effects.